InvestorsHub Logo
icon url

DewDiligence

09/11/07 2:48 PM

#1805 RE: go seek #1801

>it is my understanding IDIX has primary responsibility for US sales...<

Someone has to be named the lead party for accounting purposes and, in the US, the named lead party is IDIX.

But NVS is actually calling the shots. Make no mistake about it.
icon url

keitern

09/11/07 2:50 PM

#1806 RE: go seek #1801

Some (on message boards) have questioned the efficacy of Tyzeka and this report would seem to put that to rest.
icon url

dewophile

09/11/07 2:59 PM

#1809 RE: go seek #1801

US market "more challenging"

yes, and i think the reason why is the AASLD guidelines, as pointed out by gofish. telbiv gets far mroe favorable endorsement in the canadian guidelines (also pointed out by gofish), and probably the same is unfolding in other ex-US territories

not only was telbiv given the ok as first line in canadian guidelines, it was the only direct acting antiviral NOT mentioned to avoid in HIV coinfected pts not on HAART